Trial reportCognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology2026
Facial Emotion Recognition Ability May Improve in Alzheimer Disease: A Pilot Study.
Trial report in Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFacial emotion recognition (FER) deficits in Alzheimer disease (AD) are associated with atypical eye-gaze strategies and exacerbated behavioral and psychological symptoms of dementia (BPSD). This results in increased caregiver burden and impacts social interactions and quality of life.
objectiveTo evaluate the effects of Training of Affect Recognition (TAR), a targeted cognitive remediation program, on FER, eye-gaze patterns, and BPSD in individuals with AD, as well as caregiver burden. We hypothesized improvements in emotional processing and associated clinical outcomes.
methodsTwenty-four patient-caregiver dyads participated in this single-blind randomized controlled pilot study. Each patient was assigned to participate in the TAR program (ie, the AD-TAR group; n = 12) or to receive cognitive stimulation intervention twice weekly for 6 weeks (ie, the AD-CS group; n = 12). We assessed FER using static ( n = 24) and dynamic ( n = 16) stimuli with eye-tracking. We used the Neuropsychiatric Inventory to assess BPSD and the Zarit Burden Interview to assess caregiver burden. Each assessment was completed at baseline, post-intervention, and 1-month follow-up.
resultsThe AD-TAR group showed improvements in static FER accuracy and recognition speed, as well as increased dynamic FER speed. There were concomitant beneficial changes in eye-gaze strategies in static FER and reinforced observation strategies for dynamic FER. Reductions in BPSD and caregiver burden persisted at the 1-month follow-up.
conclusionTargeted FER remediation is a promising intervention for improving emotional processing in AD, with potential clinical implications for managing BPSD and enhancing quality of life for individuals with AD and their caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.